Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hematologic Diseases 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Diseases 1Abiraterone Acetate 1

Interventions

Imatinib Mesylate 28nilotinib 21Cytarabine 8Cyclophosphamide 8Methotrexate 7Peripheral Blood Stem Cell Transplantation 6Interferon-alpha 6Hydroxyurea 6bosutinib 5asciminib 5Whole-Body Irradiation 5Mycophenolic Acid 5Tacrolimus 4Dasatinib 4Busulfan 4peginterferon alfa-2a 3fludarabine phosphate 3fludarabine 3Radiotherapy 3Cyclosporine 3sargramostim 2ponatinib 2Sirolimus 2Idarubicin 2Etoposide 2BID protein, human 2thymoglobulin 1peginterferon alfa-2b 1pegaspargase 1olverembatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × BID protein, human × Clear all
NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Novartis

Phase 3 Completed
199 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02627677 2021-11-26

OPTIC-2L

Takeda

Phase 3 Terminated
44 enrolled 22 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡